{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:41Z","timestamp":1791316781478,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA241191"],"award-info":[{"award-number":["R01 CA241191"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA219836"],"award-info":[{"award-number":["R01 CA219836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA260239"],"award-info":[{"award-number":["R01 CA260239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA260239"],"award-info":[{"award-number":["R01 CA260239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA242003"],"award-info":[{"award-number":["R01 CA242003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA241191"],"award-info":[{"award-number":["R01 CA241191"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA242003"],"award-info":[{"award-number":["R01 CA242003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA241191"],"award-info":[{"award-number":["R01 CA241191"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA219836"],"award-info":[{"award-number":["R01 CA219836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA260239"],"award-info":[{"award-number":["R01 CA260239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["8JK04"],"award-info":[{"award-number":["8JK04"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["8JK04"],"award-info":[{"award-number":["8JK04"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family anti-apoptotic proteins, except BCL-2 inhibitors, are not clinically relevant because of various on-target toxicities. We, therefore, aimed to develop an effective and safe strategy targeting these anti-apoptotic proteins with DT2216 (our platelet-sparing BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    degrader) and AZD8055 (an mTOR inhibitor) to avoid associated on-target toxicities while synergistically optimizing tumor response. Through BH3 mimetic screening, we identified a subset of SCLC cell lines that is co-dependent on BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and MCL-1. After screening inhibitors of selected tumorigenic pathways, we found that AZD8055 selectively downregulates MCL-1 in SCLC cells and its combination with DT2216 synergistically killed BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    \/MCL-1 co-dependent SCLC cells, but not normal cells. Mechanistically, the combination caused BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    degradation and suppression of MCL-1 expression, and thus disrupted MCL-1 interaction with BIM leading to an enhanced apoptotic induction. In vivo, the DT2216\u2009+\u2009AZD8055 combination significantly inhibited the growth of cell line-derived and patient-derived xenografts and reduced tumor burden accompanied by increased survival in a genetically engineered mouse model of SCLC without causing appreciable thrombocytopenia or other normal tissue injuries. Thus, these preclinical findings lay a strong foundation for future clinical studies to test DT2216\u2009+\u2009mTOR inhibitor combinations in a subset of SCLC patients whose tumors are co-driven by BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and MCL-1.\n                  <\/jats:p>","DOI":"10.1038\/s41420-022-01296-8","type":"journal-article","created":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T23:22:14Z","timestamp":1672615334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-8846","authenticated-orcid":false,"given":"Sajid","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kellish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-0674","authenticated-orcid":false,"given":"Nick","family":"Connis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Thummuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekananda","family":"Budamagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umasankar","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingtao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-0346","authenticated-orcid":false,"given":"Weizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-6663","authenticated-orcid":false,"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hromas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zajac-Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8565-1854","authenticated-orcid":false,"given":"Frederic J.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.106","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:765.","journal-title":"Nat Rev Cancer"},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12:47.","journal-title":"J Hematol Oncol"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330.","journal-title":"J Clin Oncol"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jtho.2020.01.016","volume":"15","author":"JT Poirier","year":"2020","unstructured":"Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, et al. New approaches to SCLC therapy: from the laboratory to the clinic. J Thorac Oncol. 2020;15:520\u201340.","journal-title":"J Thorac Oncol"},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","volume":"1","author":"CA Stewart","year":"2020","unstructured":"Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423\u201336.","journal-title":"Nat Cancer"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"1296_CR8","doi-asserted-by":"publisher","first-page":"102953","DOI":"10.1016\/j.isci.2021.102953","volume":"24","author":"K Pozo","year":"2021","unstructured":"Pozo K, Kollipara RK, Kelenis DP, Rodarte KE, Ullrich MS, Zhang X, et al. ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. iScience. 2021;24:102953.","journal-title":"iScience"},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346\u2013360.e7.","journal-title":"Cancer Cell"},{"key":"1296_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16078","volume":"8","author":"A Inoue-Yamauchi","year":"2017","unstructured":"Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078.","journal-title":"Nat Commun"},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","volume":"14","author":"AR Shoemaker","year":"2008","unstructured":"Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14:3268\u201377.","journal-title":"Clin Cancer Res"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163\u20139.","journal-title":"Clin Cancer Res"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663\u201374.","journal-title":"Blood"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943\u201351.","journal-title":"Cell Death Differ"},{"key":"1296_CR16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","volume":"13","author":"Y He","year":"2020","unstructured":"He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13:95.","journal-title":"J Hematol Oncol"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"112186","DOI":"10.1016\/j.ejmech.2020.112186","volume":"192","author":"X Zhang","year":"2020","unstructured":"Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186.","journal-title":"Eur J Med Chem"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.37349\/etat.2020.00017","volume":"1","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang X, Liu X, Khan S, Zhou D, Zheng G. PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. Explor Target Antitumor Ther. 2020;1:259\u201372.","journal-title":"Explor Target Antitumor Ther"},{"key":"1296_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15838-0","volume":"11","author":"Y He","year":"2020","unstructured":"He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020;11:1996.","journal-title":"Nat Commun"},{"key":"1296_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05815-z","volume":"9","author":"RS Soderquist","year":"2018","unstructured":"Soderquist RS, Crawford L, Liu E, Lu M, Agarwal A, Anderson GR, et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat Commun. 2018;9:3513.","journal-title":"Nat Commun"},{"key":"1296_CR22","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27:1365\u201377.","journal-title":"Genes Dev"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/hep.23126","volume":"50","author":"H Hikita","year":"2009","unstructured":"Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009;50:1217\u201326.","journal-title":"Hepatology"},{"key":"1296_CR24","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","volume":"37","author":"CE Weeden","year":"2018","unstructured":"Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, et al. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene 2018;37:4475\u201388.","journal-title":"Oncogene"},{"key":"1296_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozreti\u0107 L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47\u201353.","journal-title":"Nature"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","volume":"112","author":"AC Faber","year":"2015","unstructured":"Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci USA. 2015;112:E1288\u201396.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ccell.2019.03.007","volume":"35","author":"M Elgendy","year":"2019","unstructured":"Elgendy M, Cir\u00f2 M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3\u03b2-MCL-1 Axis. Cancer Cell. 2019;35:798\u2013815.e5.","journal-title":"Cancer Cell"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1158\/2159-8290.CD-13-0315","volume":"4","author":"AC Faber","year":"2014","unstructured":"Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2\/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014;4:42\u201352.","journal-title":"Cancer Discov"},{"key":"1296_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-16-0342","volume":"16","author":"C P\u00e9tigny-Lechartier","year":"2017","unstructured":"P\u00e9tigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, et al. The mTORC1\/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1\/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737. Mol Cancer Ther. 2017;16:102\u201315.","journal-title":"Mol Cancer Ther"},{"key":"1296_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"key":"1296_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1296_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2018.06.019","volume":"432","author":"Y-C Lee","year":"2018","unstructured":"Lee Y-C, Wang L-J, Huang C-H, Shi Y-J, Chang L-S. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. Cancer Lett. 2018;432:191\u2013204.","journal-title":"Cancer Lett"},{"key":"1296_CR33","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1158\/0008-5472.CAN-09-4228","volume":"70","author":"BE Schaffer","year":"2010","unstructured":"Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010;70:3877\u201383.","journal-title":"Cancer Res"},{"key":"1296_CR34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1172\/JCI121323","volume":"129","author":"P Kellish","year":"2019","unstructured":"Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, et al. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J Clin Invest. 2019;129:2279\u201392.","journal-title":"J Clin Invest"},{"key":"1296_CR35","first-page":"319","volume":"49","author":"MH Ullman-Culler\u00e9","year":"1999","unstructured":"Ullman-Culler\u00e9 MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319\u201323.","journal-title":"Lab Anim Sci"},{"key":"1296_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21573-x","volume":"12","author":"R Kolb","year":"2021","unstructured":"Kolb R, De U, Khan S, Luo Y, Kim M-C, Yu H, et al. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:1281.","journal-title":"Nat Commun"},{"key":"1296_CR37","doi-asserted-by":"publisher","first-page":"369ra175","DOI":"10.1126\/scitranslmed.aae0348","volume":"8","author":"GR Anderson","year":"2016","unstructured":"Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med. 2016;8:369ra175.","journal-title":"Sci Transl Med"},{"key":"1296_CR38","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/0008-5472.CAN-13-3460","volume":"74","author":"EE Gardner","year":"2014","unstructured":"Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res. 2014;74:2846\u201356.","journal-title":"Cancer Res"},{"key":"1296_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","volume":"21","author":"D Thummuri","year":"2022","unstructured":"Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther. 2022;21:184\u201392.","journal-title":"Mol Cancer Ther"},{"key":"1296_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1568-3","volume":"10","author":"EF Lee","year":"2019","unstructured":"Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10:342.","journal-title":"Cell Death Dis"},{"key":"1296_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"},{"key":"1296_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","volume":"1877","author":"C Fraser","year":"2019","unstructured":"Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 2019;1877:61\u201376.","journal-title":"Methods Mol Biol"},{"key":"1296_CR43","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.1410419111","volume":"111","author":"A Augustyn","year":"2014","unstructured":"Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111:14788\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1296_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcb.240630505","volume":"24","author":"RM Phelps","year":"1996","unstructured":"Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996;24:32\u201391.","journal-title":"J Cell Biochem Suppl"},{"key":"1296_CR45","doi-asserted-by":"publisher","first-page":"117976","DOI":"10.1016\/j.lfs.2020.117976","volume":"256","author":"S Khan","year":"2020","unstructured":"Khan S, Shukla S, Farhan M, Sinha S, Lakra AD, Penta D, et al. Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1\/PAK1\/\u03b2-catenin signaling axis. Life Sci. 2020;256:117976.","journal-title":"Life Sci"},{"key":"1296_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2014.10.028","volume":"58","author":"S Khan","year":"2015","unstructured":"Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2\/ERK1\/2\/MMP-9 signaling. Int J Biochem Cell Biol. 2015;58:1\u201316.","journal-title":"Int J Biochem Cell Biol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01296-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:06:18Z","timestamp":1672891578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01296-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.12.507616","asserted-by":"object"}]},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK, DT, PZ, GZ, and DZ are inventors of two patent applications for use of BCL-X<sub>L<\/sub> PROTACs as senolytic and antitumor agents. RH, GZ, and DZ are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-X<sub>L<\/sub>\/2 PROTACs to treat cancer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}